Gout is a condition where a waste product called uric acid builds up in the body. Normally, uric acid dissolves in the blood, gets processed by the kidneys, and leaves the body in the urine. A small proportion of uric acid is also excreted by the intestines. With gout, there is too much uric acid in the body, either because the body makes too much uric acid, or the kidneys cannot remove as much as should.
Signs and symptoms of Chronic Refractory Gout include chronic arthritis; joints with swelling, redness, and intense pain, and tophi (lumps around hands, elbows, and other body parts). Diagnosis of Refractory gout involves the measurement of serum uric acid levels and examination of the signs and symptoms associated with gout. A more definitive diagnosis is based on the presence of monosodium urate crystals in joint aspiration fluid. Imaging tools and techniques utilized in gout can include conventional radiography, ultrasound, computed tomography, dual-energy computed tomography, magnetic resonance imaging, and nuclear medicine.
Get FREE sample copy at https://www.delveinsight.com/sample-request/chronic-refractory-gout-market
The Chronic Refractory Gout market report also covers emerging drugs, current treatment practices, Chronic Refractory Gout market size and share of the individual therapies, current and forecasted Chronic Refractory Gout Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Chronic Refractory Gout treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Chronic Refractory Gout Market Key Facts
According to the National Kidney Foundation, gout affected 8.3 million adults in the US, which includes 6.1 million men and 2.2 million women.
According to the study conducted by Gordon et al. (2012), titled “Refractory Gout: An overview of pathogenesis and treatment”, Gout is the most common form of inflammatory arthritis. Prevalence in the US during 2007-2008 is estimated to be 3.9%. Refractory gout estimated to be 2% of all gout patients.
In the study conducted by Kuo et al. (2015), titled “Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study,” the prevalence of gout rose by 63.9% between 1997‒2012.
Key Benefits of Chronic Refractory Gout Market Report
Chronic Refractory Gout market report provides an in-depth analysis of Chronic Refractory Gout Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Chronic Refractory Gout market report will help in developing business strategies by understanding the Chronic Refractory Gout Market trends & developments, key players and future market competition that will shape and drive the Chronic Refractory Gout market in the upcoming years.
The Chronic Refractory Gout market report covers Chronic Refractory Gout market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Chronic Refractory Gout patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The market size of Chronic Refractory Gout is expected to increase during the forecasted period owing to the rising prevalence of gout in the 7MM. Similarly, the factors such as approval of novel treatment options, increasing prevalence of Gout, improving healthcare infrastructure in emerging economies, and increased investment by pharmaceutical companies for research will further fuel the market in a positive direction.
The Chronic Refractory Gout market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic Refractory Gout market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Chronic Refractory Gout market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Chronic Refractory Gout epidemiology section covers insights about historical and current Chronic Refractory Gout patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted Chronic Refractory Gout epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Chronic Refractory Gout Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Gout market or expected to get launched in the market during the study period. The analysis covers Chronic Refractory Gout market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The key companies in the Chronic Refractory Gout market include:
Chronic Refractory Gout Therapies covered;
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Refractory Gout Competitive Intelligence Analysis
4. Chronic Refractory Gout Market Overview at a Glance
5. Chronic Refractory Gout Disease Background and Overview
6. Chronic Refractory Gout Patient Journey
7. Chronic Refractory Gout Epidemiology and Patient Population
8. Chronic Refractory Gout Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Refractory Gout Unmet Needs
10. Key Endpoints of Chronic Refractory Gout Treatment
11. Chronic Refractory Gout Marketed Products
12. Chronic Refractory Gout Emerging Therapies
13. Chronic Refractory Gout Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Refractory Gout Market Outlook (7 major markets)
16. Chronic Refractory Gout Access and Reimbursement Overview
17. KOL Views on the Chronic Refractory Gout Market.
18. Chronic Refractory Gout Market Drivers
19. Chronic Refractory Gout Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd 2432
City: Las Vegas
Country: United States